Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

4.9%

10 terminated/withdrawn out of 203 trials

Success Rate

94.1%

+7.6% vs industry average

Late-Stage Pipeline

27%

55 trials in Phase 3/4

Results Transparency

9%

14 of 160 completed trials have results

Key Signals

11 recruiting14 with results10 terminated

Enrollment Performance

Analytics

Phase 1
112(58.3%)
Phase 3
42(21.9%)
Phase 2
24(12.5%)
Phase 4
13(6.8%)
N/A
1(0.5%)
192Total
Phase 1(112)
Phase 3(42)
Phase 2(24)
Phase 4(13)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (203)

Showing 20 of 203 trials
NCT07219589Phase 1Recruiting

A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants

Role: lead

NCT04775706Phase 2Recruiting

Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

Role: lead

NCT07527650Phase 2Not Yet Recruiting

Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

Role: lead

NCT07205900Phase 2Active Not Recruiting

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

Role: lead

NCT06234397Phase 1Recruiting

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

Role: lead

NCT07359105Not ApplicableRecruiting

Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)

Role: collaborator

NCT07449754Phase 2Recruiting

Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

Role: lead

NCT07379333Phase 3Not Yet Recruiting

A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

Role: lead

NCT07297693Phase 1Not Yet Recruiting

A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers

Role: lead

NCT06724016Phase 1Recruiting

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

Role: lead

NCT06595004Phase 3Completed

A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients

Role: lead

NCT04505436Phase 2Active Not Recruiting

Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects

Role: lead

NCT06858397Phase 1Recruiting

A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease

Role: collaborator

NCT04768686Phase 2Completed

FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer

Role: lead

NCT01282073Phase 3Completed

Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy

Role: collaborator

NCT06174766Phase 3Recruiting

A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients

Role: lead

NCT06174779Phase 3Active Not Recruiting

A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus

Role: lead

NCT06481098Phase 1Completed

A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

Role: lead

NCT05598151Phase 1Recruiting

Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors

Role: lead

NCT05711381Phase 1Completed

Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function

Role: lead